Colorectal Surveillance in IBD: Updated BSG Guidance: Gut | 2026

Introduction

The updated British Society of Gastroenterology guideline reflects an important change in the way we think about colorectal cancer surveillance in inflammatory bowel disease. The modern message is not that every patient with colonic IBD should automatically undergo the same surveillance forever, but that surveillance should be more precise, more individualised, and more closely linked to actual cancer risk. Although the risk of colorectal cancer in IBD is lower than older literature suggested, it still remains meaningfully higher than in the general population, especially in those with longstanding colitis, persistent inflammation, primary sclerosing cholangitis, dysplasia, strictures, or extensive disease. The guideline, therefore, shifts the field from a rigid surveillance model to a risk-adapted, quality-driven, patient-centred approach.

Key Points

Patients with colonic IBD still have a higher risk of colorectal cancer and colorectal cancer-related death than the general population, even in the modern treatment era.

The risk is no longer as high as older historical studies suggested, which means surveillance should now be more personalised rather than automatically intensive for everyone.

Surveillance colonoscopy should begin 8 years after symptom onset in patients with colonic IBD.

In patients with primary sclerosing cholangitis, surveillance should begin immediately at diagnosis because this remains one of the highest-risk groups.

Patients with ulcerative proctitis alone or Crohn’s disease without colonic involvement generally do not need IBD-specific surveillance and should instead follow population screening pathways.

Persistent inflammation is the single most important modifiable driver of colorectal neoplasia in IBD, so mucosal healing is also a cancer prevention strategy.

Surveillance intervals should be based on risk, with annual surveillance for high-risk patients, 3-yearly surveillance for intermediate-risk patients, and much less frequent reassessment for very low-risk patients.

Some patients with very low inflammatory burden and no additional risk factors may have a colorectal cancer risk close to the general population and may not need lifelong intensive surveillance.

The guideline strongly supports use of multivariable risk assessment rather than relying only on the single highest risk factor.

A major practical advance is the use of the web-based IBD dysplasia risk calculator, which helps clinicians individualize surveillance intervals more accurately.

Post-colonoscopy colorectal cancer is substantially more common in IBD than in sporadic colorectal cancer, showing that surveillance quality matters as much as surveillance frequency.

Many failures in surveillance are caused by delayed colonoscopy, missed appointments, poor systems, and inadequate follow-up rather than by biology alone.

High-definition colonoscopy should now be considered the standard for IBD surveillance, and standard-definition colonoscopy is no longer adequate.

Dye-based chromoendoscopy offers an additional benefit for dysplasia detection and remains the preferred enhanced imaging technique when expertise is available.

Current artificial intelligence systems are not yet ready for routine IBD dysplasia surveillance because they have not been adequately trained for IBD-specific lesions.

Targeted biopsies are preferred in most surveillance procedures, but random or segmental biopsies still have a role in selected high-risk settings such as PSC, previous dysplasia, retained rectum, or pouch surveillance.

Most visible dysplastic lesions in colitis-affected segments can now be managed endoscopically, ideally with complete en bloc resection, rather than proceeding directly to surgery.

Invisible dysplasia remains a serious finding and should always trigger repeat expert colonoscopy with chromoendoscopy and careful mapping biopsies within a short interval.

Multifocal invisible low-grade dysplasia or invisible high-grade dysplasia usually shifts management toward colectomy because the future cancer risk is high.

Every case of dysplasia in a colitis-affected segment should be discussed in a multidisciplinary team because management decisions now depend on lesion visibility, grade, resectability, patient risk factors, and patient preference.

Conclusion

This updated BSG guideline brings colorectal surveillance in IBD firmly into the era of precision medicine. Its most important message is that surveillance should no longer be viewed as a uniform lifelong protocol, but as a carefully tailored strategy based on inflammatory burden, dysplasia risk, colonoscopy quality, and patient-specific factors. For the practicing clinician, the real advances are the move toward dynamic risk stratification, the emphasis on high-quality high-definition colonoscopy, the selective use of chromoendoscopy and biopsies, and the recognition that many patients can be managed more intelligently rather than simply more intensively.